{"id":55549,"date":"2022-12-22T14:39:03","date_gmt":"2022-12-22T14:39:03","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&p=55549"},"modified":"2022-12-22T14:39:03","modified_gmt":"2022-12-22T14:39:03","slug":"mafalda-oliveira-sabcs-2022-camizestrant-vs-fulvestrant-in-women-with-advanced-er-her2-breast-cancer-the-serena-2-trial","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/breast-cancer\/conference-hub\/mafalda-oliveira-sabcs-2022-camizestrant-vs-fulvestrant-in-women-with-advanced-er-her2-breast-cancer-the-serena-2-trial\/","title":{"rendered":"Mafalda Oliveira, SABCS 2022: Camizestrant vs fulvestrant in women with advanced ER+ HER2- breast cancer: The SERENA-2 trial"},"content":{"rendered":"
The SERENA-2 trial (NCT04214288)<\/a> is a randomised, multicentre phase II trial evaluating camizestrant at several dose levels compared to fulvestrant in advanced ER-positive, HER2-negative breast cancer. In this touchONCOLOGY interview, we speak with <\/span>Dr\u00a0Mafalda Oliveira <\/b>(Vall d\u2019Hebron University Hospital Barcelona, Spain) who gives an overview of the SERENA-2 trial and the advantages<\/span> for the use of camizestrant over fulvestrant <\/span>as well as discussing the next steps in the clinical development of camizestrant.<\/span><\/span><\/p>\n The abstract entitled \u2018Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial<\/span><\/span>\u2019 was presented at San Antonio Breast Cancer Symposium\u00a0(SABCS)<\/a>, 06\u201310, December, 2022.<\/span><\/p>\n Questions<\/b>:<\/span><\/p>\n Disclosures<\/b>: Mafalda Oliveira is a consultant for AstraZeneca, GuardantHealth, Roche, MSD, Relay Therapeutics, Pfizer, SeaGen, iTEOS and Gilead and discloses grant\/research support from AstraZeneca, Ayala Pharmaceuticals, Boehringer-Ingelheim, Genentech, GSK, Novartis, PUMA Biotechnology, Roche, SeaGen and Zenith Epigenetics.<\/span><\/p>\n Support<\/b>: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen<\/span><\/p>\n Filmed as a highlight of <\/i><\/b>SABCS 2022<\/i><\/b><\/a><\/p>\n\n
\n<\/span><\/li>\n
\n<\/span><\/li>\n
\n<\/span><\/li>\n
\n<\/span><\/li>\n